Class of 2023
Scientific Areas of Expertise: MAP Kinase Pathway Targeted Therapies, Oncology Drug Development, Therapeutic Resistance
For groundbreaking translational discoveries and seminal contributions to the development of vemurafenib and other therapeutic agents for the treatment of melanoma, translating investigations of the BRAF V600E somatic mutation in cancer into effective therapies, including the FDA-approved five-drug series for melanoma.